secwatch.observer — SEC 8-K summary
======================================

Issuer:     TFF Pharmaceuticals, Inc. (—)
CIK:        0001733413
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001213900-24-027199
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TFF Pharmaceuticals FY2023 net loss $21.2M, cash $5.5M; TFF TAC positive data
-----------------------------------------------------------------------------

- Cash $5.5M at Dec 31, 2023; raised $1.2M gross in March 2024 offering plus warrants at $8.00.
- FY2023 net loss $21.2M (down from $31.8M in 2022); R&D $12.1M (-35%), G&A $10.6M (-23%).
- Phase 2 TFF TAC: 8/8 patients transitioned from oral Tacrolimus, no acute rejection, 4/4 continued to long-term extension.
- TFF VORI: 5/6 completed patients achieved clinical and mycologic response; no IPA-related mortality.
- Company prioritizing TFF TAC, exploring strategic alternatives for TFF VORI; new board members appointed in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733413/000121390024027199/0001213900-24-027199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733413/000121390024027199/ea0202827-8k_tff.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-027199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer